Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data: Difference between revisions
Jump to navigation
Jump to search
(→Amgen) |
(→Who) |
||
| Line 15: | Line 15: | ||
** 2007 - Ilypsa, Inc. | ** 2007 - Ilypsa, Inc. | ||
** 2007 - Alantos Pharmaceuticals Holdings, Inc. | ** 2007 - Alantos Pharmaceuticals Holdings, Inc. | ||
* Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9Billion (http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=8632C7AC-1633-4198-8551-BB79570C668D) | |||
===What=== | ===What=== | ||
Revision as of 21:41, 6 April 2009
NIH
Celera
Amgen
Who
- 14,000 employees
- History of acquisition (from Wikipedia):
- 1994 - Synergen, Inc.
- 2000 - Kinetix Pharmaceuticals, Inc.
- 2002 - Immunex Corporation
- 2004 - Tularik, Inc.
- 2006 - Abgenix, Inc.
- 2006 - Avidia, Inc.
- 2007 - Ilypsa, Inc.
- 2007 - Alantos Pharmaceuticals Holdings, Inc.
- Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9Billion (http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=8632C7AC-1633-4198-8551-BB79570C668D)
What
- ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
- drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
Where
News
Commons-Based, Peer-Production, and Open Access News
- Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
Genentech
Genzyme
Gilead Sciences
Biogen Idec
Cephalon
MedImmune
Celgene
Abraxis BioScience
ImClone Systems
IP Profile of Biggest for-profit companies in BGP